Saturday 17 October 2026
Export ATNM’s income statement to Excel — free account
Actinium Pharmaceuticals, Inc.
ATNM Healthcare Biotechnology
Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023. In the quarter to June 2026, revenue grew 77,677.8%, EPS grew 504.6% and free cash flow fell 4.91%, each against the same quarter a year earlier.
1.13
0.07
+6.60%
Follow ATNM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(133.09%) | (166.96%) | (167.66%) | 45.86% | |
| (50.05%) | (52.67%) | (41.15%) | 21.92% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(72.45%) | (81.25%) | (64.87%) | 38.75% | |
Average Days of Receivables |
0.00 | — | — | 0.00 | |
Free Cash Flow per Share |
(0.80) | (0.79) | (0.74) | (0.74) | |
Free Cash Flow |
(25.04) | (24.68) | (22.98) | (23.25) | |
Capital Expenditures |
— | (0.10) | (0.11) | (0.58) | |
| Other line items | |||||
Cash ROIC |
(37.28%) | (44.21%) | (51.72%) | (34.81%) | |
Accounts Receivable Turnover |
0.00 | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
12,021.11% | 0.00% | 0.00% | 51.58% | |
Selling, General and Administrative Expense of Revenue |
8,772.22% | 0.00% | 0.00% | 21.09% | |
Share Based Compensation of Revenue |
5,768.33% | 0.00% | 0.00% | 0.71% | |
Operating CF/Net income |
0.72 | 0.73 | 0.97 | (2.00) | |
Depreciation/Fixed assets |
3.62 | 2.78 | 3.12 | 1.25 | |
Capex/Depreciation |
0.00 | (0.13) | (0.13) | (0.67) | |
Revenue per Share |
0.01 | 0.00 | 0.00 | 1.12 | |
Operating CF per Share |
(0.80) | (0.79) | (0.73) | (0.72) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.02 |
Columns are period end dates